Engineered Biomatrices: Transforming Science with Synthetic Serum and Urine

The growing demand for reliable biological matrices drives the production of synthetic serum and urine, offering consistency, safety, and ethical advantages that transform research, diagnostics, and industrial applications.

Life Sciences Review | Monday, June 23, 2025

The increasing demand for consistent, reliable, and contaminant-free biological matrices in various scientific and industrial applications drives the manufacturing of synthetic serum and urine. These synthetic alternatives are rapidly displacing their naturally derived counterparts due to inherent advantages in reproducibility, stability, and safety, paving the way for more precise and ethical research, diagnostic, and product development endeavors.

Synthetic Serum: A Paradigm Shift in Biological Matrices

Research and diagnostic assays heavily rely on animal or human-derived serum. While once indispensable, natural serum presents significant limitations, including inherent batch-to-batch variability in composition, the potential for adventitious agent contamination, and ethical concerns associated with animal sourcing, such as animal welfare and the use of large numbers of animals. Synthetic serum has emerged as a superior alternative, meticulously engineered to mimic the complex biochemical environment of biological serum while eliminating these drawbacks.

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

The core of synthetic serum manufacturing lies in precisely controlled formulation. These advanced matrices are composed of highly purified, defined components, typically including various salts, amino acids, vitamins, growth factors, and lipids, all combined in specific concentrations to replicate the physiological properties and functions of natural serum. This precise control over composition is paramount, as it ensures unparalleled lot-to-lot consistency, a critical factor for reproducible experimental results in research and reliable calibration and quality control in diagnostic kit manufacturing.

Recent advancements in synthetic serum production focus on enhancing its mimicry of physiological conditions and expanding its applicability. This includes the development of formulations tailored for specific cell culture applications, where the absence of undefined components often found in natural serum reduces experimental noise and improves the interpretability of results. Furthermore, efforts are underway to incorporate more complex biomolecules, such as recombinant proteins and growth factors, into synthetic serum formulations, allowing for even greater physiological relevance and supporting more intricate biological studies, including those involving sensitive cell lines or specialized tissue engineering. The emphasis is on creating a comprehensive and robust environment that supports cell growth, proliferation, and differentiation as effectively as, if not better than, natural serum, without the associated risks and variability.

The manufacturing process for synthetic serum emphasizes purity and scalability. Advanced filtration and sterilization techniques are employed to ensure the absence of microbial contaminants, endotoxins, and other undesirable impurities that could interfere with sensitive assays or compromise cell viability. The use of highly controlled, industrial-scale production facilities allows for the consistent manufacture of large batches, meeting the growing global demand from the biotechnology, pharmaceutical, and diagnostic industries. This scalability, coupled with reduced reliance on biological sourcing, also contributes to more sustainable and cost-effective production.

Synthetic Urine: Precision and Purity for Diverse Testing

Parallel to the advancements in synthetic serum, synthetic urine has revolutionized various testing and calibration applications. Natural urine, like natural serum, exhibits considerable variability influenced by diet, hydration, health status, and medication, rendering it an unreliable standard for consistent testing. Synthetic urine addresses these challenges by providing a standardized, controlled, and contaminant-free medium.

The composition of synthetic urine is meticulously designed to replicate the key physical and chemical properties of human urine, including specific gravity, pH, creatinine levels, urea concentration, and the presence of various ionic compounds. Modern manufacturing processes for synthetic urine involve the precise dissolution of high-purity chemicals in deionized water, followed by rigorous quality control checks to ensure each batch meets predefined specifications. This precision instills confidence in its reliability for a wide range of testing applications.

The latest developments in synthetic urine production are geared towards enhancing its utility in specialized applications. This includes the creation of formulations that mimic urine under specific pathological conditions, such as diabetes or kidney disease, allowing for the development and validation of new diagnostic tests for these diseases. For instance, synthetic urine can be engineered to contain specific biomarkers at defined concentrations, providing an ideal matrix for calibrating and validating novel biosensors and diagnostic devices. The ability to control individual parameters, such as the presence or absence of specific metabolites, makes synthetic urine an invaluable tool for isolating and studying the impact of particular components on test outcomes.

Manufacturing facilities for synthetic urine employ stringent quality assurance protocols to guarantee batch consistency and sterility. This is crucial for applications where even minute variations could compromise test accuracy, such as in the development of point-of-care diagnostic devices or the quality control of urinalysis equipment. The trend is towards highly automated and precise blending systems that minimize human intervention and maximize reproducibility, ensuring a uniform product that serves as a reliable benchmark across diverse industries.

Applications across Industries

The widespread adoption of synthetic serum and urine is evident across numerous sectors. In the biopharmaceutical industry, synthetic serum is foundational for cell culture in vaccine production, therapeutic protein manufacturing, and regenerative medicine. Its defined composition reduces variability in cell growth and product yield, streamlining drug development and manufacturing processes. For diagnostic companies, both synthetic serum and urine are indispensable for developing, calibrating, and performing quality control on in vitro diagnostic kits, ensuring the accuracy and reliability of medical tests. This includes immunoassays, clinical chemistry analyzers, and molecular diagnostic platforms.

Beyond medical applications, synthetic urine finds extensive use in the product development and testing industry. Manufacturers of hygiene products, such as diapers, sanitary pads, and adult incontinence products, rely on synthetic urine to assess absorbency, leakage, and odor control under standardized conditions. Similarly, the automotive industry utilizes synthetic urine to test corrosion resistance of materials in contact with biological fluids. In the realm of forensic science and toxicology, synthetic urine serves as a crucial control sample for calibrating drug detection equipment and validating testing methodologies, ensuring the integrity and accuracy of analytical results.

The future of synthetic serum and urine manufacturing is poised for continued innovation. Driven by the increasing sophistication of biological research and diagnostic needs, there is a clear trend towards even more physiologically relevant and complex synthetic matrices. This will likely involve the incorporation of additional classes of biomolecules, such as exosomal components and specific microRNAs, to enable more nuanced studies of cellular communication and disease pathogenesis, opening up new possibilities for research and discovery.

Advancements in high-throughput screening and automation are expected to drive the development of customized synthetic matrices, enabling researchers to tailor compositions for specific experimental designs rapidly. The integration of AI and machine learning could also play a significant role in optimizing formulations to achieve desired biological outcomes, thereby further accelerating research and development cycles. As the scientific community continues to prioritize reproducibility, ethical sourcing, and cost-efficiency, synthetic serum and urine will undoubtedly remain at the forefront of essential laboratory and industrial tools, continuing their trajectory of innovation and widespread adoption.

More in News

Growing Concerns About Data Continuity in Biopharma Evidence Generation

One of the common concerns within biopharma is not a matter of generating evidence per se. What makes it even harder is the possibility of sustaining a consistent stream of information through several studies or regulations over prolonged periods of time. As such, the issue of data continuity gains more importance as evidence generation software solutions are currently evaluated by potential buyers. Evidentiary initiatives are never limited to the sole scope of their objectives. Information retrieved once can become relevant several times over the life cycle of a particular product. Researchers may need to re-examine certain findings, compare results of treatment between different periods of time or study data acquired within separate research processes. It becomes especially complicated if there are no consistent information sources within an organization. Such considerations begin to impact the choice of evidence generation software. While the tools themselves are hardly ever used to produce any scientific insights directly, their contribution lies in facilitating further evidence processing and management. The problem becomes apparent as evidentiary research programs move past their initial objectives. It is rare for evidence generation initiatives to have a definite deadline or goal. Several years may pass between the start of the research process and its end, which means that there can be many staff changes, reconsiderations of previous assumptions or emergence of new questions. When information proves hard to find or analyze, the whole process can be slowed down significantly. The amount of effort spent tracking documents, verifying the integrity of information and understanding research history may prove to be considerable. At the same time, these aspects might not become a major focus of technology evaluation. Procurement conversations about evidence generation software solutions are shifting in this direction. Buyers' attention moves from operational effectiveness to information sustainability as evidence programs grow more extensive and complex. They are starting to see evidence generation software platforms as tools for sustaining knowledge over time rather than project management resources. This brings a change to the list of priorities for software developers. Features aimed at optimizing research processes are essential but buyers become concerned with data preservation as well. As such, information continuity becomes part of a solution's institutional memory function rather than just another aspect of project management. While data continuity may not be as prominent as some new trends in evidence analytics, it addresses a pressing problem faced by many biopharma teams. Evidence generation projects tend to outlast their budgets, original objectives or even the members of a team conducting research. For biopharma companies investing in such tools, the problem is shifting from acquiring new information to keeping existing data context-sensitive. ...Read more

Choosing Microbial CDMO without Losing Process Control

Commercial biologics programs rarely stall because a sponsor failed to reserve manufacturing capacity. Delays are more likely to appear when fermentation assumptions, purification readiness, assay design and batch documentation fall out of sync. Microbial manufacturing is particularly sensitive at this stage. A process that performs well during development can quickly lose momentum if harvest conditions are not fully understood or impurity clearance has not been aligned with the characteristics of the molecule. For executives evaluating a CDMO, manufacturing capacity is important, but maintaining process continuity is even more critical. The strongest CDMOs do not treat development and manufacturing as separate stages handed from one department to another. Instead, they manage them as a continuous, controlled process. Analytical strategy is developed while the process is still being refined, manufacturing constraints are identified before GMP transfer, sampling routes are planned early and documentation evolves alongside the program instead of being rebuilt for clinical or commercial manufacturing. This goes beyond administrative efficiency. It is an important part of controlling risk. Changes to analytical methods or batch records late in development can trigger comparability work and make regulatory review more challenging. "Richter BioLogics aligns well with the priorities many sponsors look for when they need microbial expertise backed by GMP manufacturing." A thorough evaluation should also examine how fermentation and purification work together in practice. Separate upstream and downstream suites can offer sponsors greater flexibility, but only if the transition between them is carefully managed. Having real-time harvest data, purification teams ready to receive material, buffers prepared in advance and clear sample routes in place helps avoid the disruption that often occurs between the bioreactor and the first chromatography step. The same level of scrutiny applies to plasmid DNA manufacturing, where supercoiled content, host-cell impurities, endotoxin burden and unwanted isoforms all influence whether the final material is suitable for its intended use. Quality systems should be assessed through evidence, not broad assurances. Every GMP manufacturing program generates extensive documentation, and that record should remain clear and consistent from raw material receipt and media preparation through in-process testing, deviations, investigations and final product release. Buyers should look at whether quality control is integrated closely enough with manufacturing to detect early process signals. They should also consider whether the CDMO has the in-house analytical expertise needed for release testing, stability studies, troubleshooting and comparability work, instead of relying on outside laboratories whenever challenges arise. "For sponsors working to demanding timelines, Richter BioLogics brings together specialized microbial expertise, disciplined documentation, in-house analytical testing and direct project coordination." Scale also deserves careful consideration. A larger facility does not automatically make decisions faster, and a smaller specialist may not have enough built-in redundancy. A better question is whether the manufacturing model gives sponsors direct access to scientific expertise while providing the GMP infrastructure needed to support late-stage development and commercial production. That balance is especially important in microbial biologics. Therapeutic proteins, antibody fragments, bacterial vaccines and plasmid DNA each bring different manufacturing demands, so buyers should look beyond broad claims about capacity and examine the depth of process and analytical expertise behind them. Richter BioLogics aligns well with the priorities many sponsors look for when they need microbial expertise backed by GMP manufacturing. Its capabilities span process development, analytical development, microbial GMP manufacturing and plasmid DNA production, including the pART plasmid platform. The company operates independent upstream and downstream processing lines across two multiproduct GMP facilities, with quality control integrated throughout manufacturing campaigns. It supports therapeutic proteins, VHH or Nanobody formats, bacterial vaccines and plasmid DNA. A long GMP manufacturing track record, recent capacity expansion, in-house analytical capabilities and a 2026 FDA inspection with zero observations provide added confidence. For sponsors working to demanding timelines, Richter BioLogics brings together specialized microbial expertise, disciplined documentation, in-house analytical testing and direct project coordination. ...Read more

Inventus welcomes senior figure from Google as a board adviser

Inventus, the only company in the world dedicated to creating purpose-built devices and technology solutions exclusively for clinical trials, has made a key appointment from Google to its advisory board. Mark Bennett, a Vice President at Google, will be working with Inventus in the capacity of Board Adviser. Bennett has more than two decades in senior leadership roles at companies including Microsoft, Sainsbury’s & Tesco. He is currently Google’s Vice President of Knowledge & Information Partnerships for the EMEA region, leading product partnerships for Search, Gemini, Maps, Commerce, Research and Ads . Bennett has spent more than 10 years in Google Partnerships across a range of teams including Knowledge & Information, Android, Google Hardware and Google Play. Bennett’s previous roles at Google include VP for Platforms and Devices Partnerships for the APAC region and Vice President for Google’s Global Android Partnerships. Bennett said he was excited to support Inventus - known for its innovative and industry leading clinical trial solutions - to help map out its next phase of growth. He said: “I’m delighted to be advising the board at Inventus. I’m impressed by the growth and strategy of the company and am looking forward to helping them accelerate that trajectory. I’ve been intrigued by the biomedical sciences sector for some time and seen how AI is an increasingly important factor for the industry. I’ll be advising Inventus on how technology can be harnessed to enhance the efficiency, effectiveness and overall impact of clinical trials, helping bring better treatments to patients faster.” Bennett is the second key appointment from Google at Inventus in recent months. Earlier this year, Jon French, Managing Director of Google’s Android Global Business, was appointed Group Managing Director at Inventus. Commenting on Bennett’s new role, French said: “I could not be more excited to welcome Mark to the Inventus advisory board. I know personally what an incredible leader Mark is. His expertise and perspective will be tremendous assets to our business. “As Inventus enters its next phase of growth, his experience, judgement and strategic vision will help shape our direction and strengthen our ability to achieve our long-term ambitions. At the heart of everything we do at Inventus is a commitment to help bring life-changing treatments to patients faster.” Bennett is the second appointment to the Inventus advisory board – he joins Stacy Hurt, chief patient officer at Parexel, who was welcomed as a Board Adviser in the summer. Parexel is a global clinical development partner. Hurt leads efforts to integrate patient perspectives into drug development and healthcare at their earliest stages. Hurt has more than two decades of leadership experience in the pharmaceutical space. She has worked for GlaxoSmithKline, Transdermal Therapeutics and Colon Cancer Coalition across sales, training and development and has over a decade of experience in patient advocacy. Steve Sanghera, CEO and Co-Founder of Inventus, said: “I am delighted to announce the exceptional appointment of Mark Bennett to the Inventus Board. Mark brings world class technology leadership and knowledge which will be instrumental in guiding our journey as we navigate how AI will shape and influence clinical trials. Mark’s appointment reflects the continuous growth of Inventus within the industry. Together with Stacy, the expertise that we now have at Inventus also demonstrates our commitment to building a business that focuses on technological excellence and the patients which sit at the heart of a clinical trial.” ...Read more

Inventus welcomes senior figure from Google as a board adviser

Specials

Engineered Biomatrices: Transforming Science with Synthetic Serum and Urine

The growing demand for reliable biological matrices drives the production of synthetic serum and urine, offering consistency, safety, and ethical advantages that transform research, diagnostics, and industrial applications.